Kite Pharma Inc (NASDAQ:KITE) announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI) and a special advisor to Kite, has received three significant awards for his achievements and career dedicated to advancing cancer research. The American Cancer Society (ACS), the largest voluntary health organization in the United States, awarded Dr. Rosenberg its Medal of Honor for his pioneering leadership in cancer immunotherapy. The Medal of Honor is the ACS’ highest honor and was presented to Dr. Rosenberg at a ceremony held in Washington, DC, on September 30, 2015. Additional recent awards include:

  • Dr. Rosenberg has been awarded the Samuel J. Heyman Service to America Medal for career achievement by the Partnership for Public Service. The “Sammies” are bestowed upon individuals to highlight excellence in the federal workforce and inspire other talented and dedicated individuals to go into public service. Dr. Rosenberg will receive his award during a gala and ceremony that is taking place tonight, October 7, in Washington, DC.
  • Susan G. Komen, the world’s largest breast cancer organization, awarded Dr. Rosenberg the Betty Ford Lifetime Achievement Award for his four decades of work in fighting cancer at the NCI. This award recognizes individuals who have committed their lives to engaging the public in the fight against breast cancer, advocating for meaningful change, and educating communities to support women and men facing the disease.  Dr. Rosenberg was recognized during the Honoring the Promise gala, which took place in Washington, DC, on September 24, 2015.

In 2012, Kite partnered with Dr. Rosenberg and the NCI under a Cooperative Research and Development Agreement (CRADA) to further the research and development of multiple chimeric antigen receptor (CAR) and T cell receptor (TCR) based product candidates for the treatment of advanced solid and hematological malignancies. Many of these product candidates are now being assessed in clinical trials and Kite has since exclusively licensed intellectual property related to certain of these product candidates.

“We have always appreciated the great honor of being able to advance cancer therapies with Steve and are thrilled that three of the most prominent awards in medicine and public service have been made in recognition of the pivotal role Steve has played in cancer care and research on the national stage,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite.  “During his long and successful career, Steve’s insights time and again have had an astounding impact on the direction of cancer research. His contributions, including to the exciting field of cancer immunotherapy, have been immense, and we are elated for Steve to receive these awards.” (Original Source)

Shares of Kite Pharma closed yesterday at $62.97. KITE has a 1-year high of $89.21 and a 1-year low of $28.55. The stock’s 50-day moving average is $57.42 and its 200-day moving average is $60.13.

On the ratings front, Kite has been the subject of a number of recent research reports. In a report issued on September 24, Maxim Group analyst Jason McCarthy reiterated a Buy rating on KITE, with a price target of $87, which represents a potential upside of 38.2% from where the stock is currently trading. Separately, on the same day, Stifel Nicolaus’ Thomas Shrader reiterated a Buy rating on the stock and has a price target of $84.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason McCarthy and Thomas Shrader have a total average return of -9.0% and -9.0% respectively. McCarthy has a success rate of 34.5% and is ranked #3468 out of 3769 analysts, while Shrader has a success rate of 35.3% and is ranked #3338.

The street is mostly Bullish on KITE stock. Out of 7 analysts who cover the stock, 6 suggest a Buy rating and one recommends to Hold the stock.

Kite Pharma Inc is a clinical-stage bio pharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.